In Brief: Chiron/Ortho v. Roche
This article was originally published in The Gray Sheet
Executive Summary
Chiron and immunodiagnostics partner Ortho Diagnostics Systems file patent infringement claims in the Northern District Court of California and in the District Court of The Hague, The Netherlands against Hoffmann La Roche alleging that Roche's hepatitis C polymerase chain reaction assays infringe Chiron's newly-issued U.S. patents 5,712,088 and 5,714,596, and its longer-standing European patent EP318,216. Both suits ask the courts to enjoin Roche from further sales of its HCV PCR tests and to pay Chiron/Ortho "unspecified damages," Chiron says. Previous HCV-related patent infringement suits brought by Chiron/Ortho resulted in settlements favoring Chiron/Ortho's European patent position. In September 1996, Chiron/Ortho and International Murex settled their patent dispute by entering a worldwide licensing agreement ("The Gray Sheet" Sept. 2, 1996, I&W-7). In October 1995, Organon Teknika agreed to stop selling its HCV assays in Europe and paid Chiron/Ortho a compensatory lump-sum payment for past infringement...
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.